What is a potential risk of using calcium channel blockers in angina management?

When utilizing calcium channel blockers for the management of angina, one notable potential risk is the development of peripheral edema. This side effect occurs because calcium channel blockers can lead to vasodilation, which increases capillary permeability and allows fluid to leak into the surrounding tissues. As a result, patients may experience swelling, particularly in the lower extremities. This side effect is significant because although it may not be as immediately concerning as other potential risks, it can affect patient comfort and adherence to the treatment regimen.

In contrast, other options such as dehydration, bradycardia, and hypoglycemia are generally not directly associated with the use of calcium channel blockers in the treatment of angina. Dehydration could be more related to other factors or medications. While bradycardia can occur with some specific calcium channel blockers, it is less common as a primary concern in most patients. Hypoglycemia is typically not a side effect involved with this class of drugs, particularly compared to beta-blockers or insulin. Thus, peripheral edema stands out as a specific and relevant risk linked with the use of calcium channel blockers in this context.